Intervacc (Q2 Review): Key catalysts nearing - Redeye

Q2 figures remain small in absolute terms and do not change our view of the case. More importantly, Intervacc has taken several steps forward, including the application for a 12-month duration of immunity and continued progress towards the US market. We lower our base case slightly to SEK1.9 (2.0).

Länk till analysen i sin helhet: https://www.redeye.se/research/1180578/intervacc-q2-review-key-catalysts-nearing?utm_source=finwire&utm_medium=RSS